EFSA’s NDA Panel assessed L-alpha-GPC manufactured chemically from phosphatidylcholine-enriched soy lecithin. The dossier covers an 85% liquid and a powder form, with specifications and manufacturing considered adequately described.

The proposed use is in food supplements at up to 203.7 mg per day, corresponding to 82.5 mg choline, for people over three years of age, including pregnant and lactating women. The Panel concluded that the Novel Food raises no safety concern under the proposed conditions.

For formulation and regulatory work, the opinion provides concrete references on composition, impurities, absorption, toxicology, target population and margins of exposure. The material is derived from soy and remains subject to applicable allergen-labelling rules.

The conclusion concerns safety, not efficacy for memory, focus or cognitive performance. The EFSA opinion is one stage of the Novel Food process and should not be presented as final authorisation or approval of health claims.

Why it matters

The opinion strengthens the regulatory pathway for a new choline source and gives formulation and procurement teams concrete specifications, use conditions and documentary points.

Evidence limit

This is a scientific safety opinion, not proof of cognitive efficacy or, by itself, final European Commission authorisation. Conditions of use and labelling requirements, including soy allergen rules, still apply.

Editorial note. This content is intended for industry professionals. It does not constitute medical advice, therapeutic guidance or regulatory advice. Read our editorial method.

Read the original source · EFSA Journal ↗